B+
Bull case
25%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
NVO
Novo Nordisk A/SBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
CagriSema approval and durable Wegovy pill demand could improve confidence in Novo's obesity franchise. Novo's 2030 ambitions include more than five multi-blockbuster launches, but these are explicitly not financial guidance.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
CagriSema remains investigational; approval, label breadth, pricing and competitive uptake are unresolved. [#PR-2026-09-21-CAGRISEMA] Company release.
Momentum
28
Value
65
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $39.00 · Bull $45.00 · Bear $29.00Analysis 2026-10-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $49.66
Why
Momentum28 · Δ7d -8.1
Value65 · Δ7d -0.2
Sentiment59 · Δ7d +2.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • CagriSema remains investigational; approval, label breadth, pricing and competitive uptake are unresolved. [#PR-2026-09-21-CAGRISEMA] Company release.
- • FDA timing for denecimig is unknown while manufacturing-facility remediation continues. [#PR-2026-10-02-DENECIMIG] Company announcement.
- • Competition, pricing pressure, a restrictive CagriSema label or further denecimig facility delays could impede growth and compress the multiple.
Catalyst clock
2026-11-04
Wegovy pill switching evidence awaits a commercial read-through
Lead driver: Value · See fundamentals
Momentum
28
8% active weight
Current posture
7d trendSoftening
Δ7d
-8.1
Δ21d
+7.7
Value
65
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.8
Sentiment
59
45% active weight
Current posture
7d trendImproving
Δ7d
+2.9
Δ21d
-23.5
Why this grade
Composite grade B. Momentum 28.5 / Value 65.3 / Sentiment 58.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-07. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$29.00
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$171.25B
Beta
1.44
Shares Out
3.35B
P/E (TTM)
14.9
P/S (TTM)
3.72
P/FCF (TTM)
127.96
Rev YoY
+4.6%
EPS YoY
-18.6%
Gross Margin
+80.7%
Op Margin
+45.4%
Net Debt
$16.35B
Current Ratio
0.87
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data